| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754717 | Clinical Lymphoma Myeloma and Leukemia | 2013 | 4 Pages |
Abstract
Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Hagop M. Kantarjian, Susan O'Brien, Jorge Cortes,